Succinylcholine Chloride Injection — Class II drug recall D-1048-2017
Terminated recall by Hospira a Pfizer Company, reported 2017-08-09, distributed in PR. Lack of Sterility Assurance
| Recall number | D-1048-2017 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Hospira a Pfizer Company, Rocky Mount, NC, United States |
| Recall initiated | 2017-06-15 |
| Classified | 2017-08-01 |
| Reported by FDA | 2017-08-09 |
| Terminated | 2020-07-20 |
| Distributed | PR |
| Countries outside the US | BB, CA, KW, PH, SG |
| Quantity | 15,034,600 |
| Reason classes | sterility |
| NDC | 00409-6629, 00409-6629-02, 00409-6629-12, 00409-6629-25 |
| Lot numbers | 74393EV, 75157EV, 75158EV, 75367EV |
| Expiration dates | 2018-05-01, 2018-06-01 |
Product
Succinylcholine Chloride Injection, USP 200 mg (20 mg/mL) Quelicin Multiple-dose vial, 10 mL, For I.V. or I.M. use. a.) one vial (NDC: 0409-6629-02), b.) 25 vial carton (NDC: 0409-6629-25).
Reason for recall
Lack of Sterility Assurance
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1048-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.